China (Mainland)
Assessedsupplier 
Azithromycin CAS NO.83905-01-5
- Min.Order: 100 Kilogram
- Payment Terms: L/C,T/T,Other
- Product Details
Keywords
- Azithromycin price
- Azithromycin CAS 83905-01-5
- Azithromycin supplier in China
Quick Details
- ProName: Azithromycin
- CasNo: 83905-01-5
- Molecular Formula: C38H72N2O12
- Appearance: white crystalline powder
- Application: Azithromycin is a semi-synthetic, ring...
- DeliveryTime: 15 days after order confirmed
- PackAge: 25kg/drum;200kg/drum as per your reque...
- Port: Shanghai, Ningbo, Tianjin, etc
- ProductionCapacity: 1 Metric Ton/Month
- Purity: 99%
- Storage: Stored in cool, dry and ventilation pl...
- Transportation: by courier door to door or by sea
- LimitNum: 100 Kilogram
Superiority
Superior quality, moderate price & quick delivery.
Details
| Azithromycin Chemical Properties |
| mp | 113-115°C |
| storage temp. | Store at -20°C |
| Stability: | Stable. Incompatible with strong oxidizing agents. |
| CAS DataBase Reference | 83905-01-5(CAS DataBase Reference) |
| EPA Substance Registry System | 1-Oxa-6-azacyclopentadecan- 15-one, 13-[(2,6-dideoxy-3-C-methyl- 3-O-methyl-.alpha.-L-ribo- hexopyranosyl)oxy]-2-ethyl- 3,4,10-trihydroxy-3,5,6,8, 10,12,14-heptamethyl-11-[[ 3,4,6-trideoxy-3-(dimethylamino)-. beta.-D-xylo-hexopyranosyl] oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S, 13S,14R)-(83905-01-5) |
| Safety Information |
| Hazard Codes | Xi |
| RTECS | RN6960000 |
| Hazardous Substances Data | 83905-01-5(Hazardous Substances Data) |
| MSDS Information |
| Provider | Language |
|---|---|
| Azithromycin | English |
| Azithromycin Usage And Synthesis |
| Chemical Properties | White Crystalline Powder |
| Usage | Labelled Azithromycin, a semi-synthetic macrolide antibiotic; related to Erythromycin A. Antibacterial. |
| Usage | Azithromycin is a semi-synthetic, ring-expanded erythromycin, produced by a Beckmann rearrangement of erythromycin oxime and reduction to the imine ether, followed by reductive methylation. Azithromycin was the first of the azalides and was designed to improve stability and biological half-life of erythromycin A, as well as improve activity against Gram negative bacteria. Since its discovery in 1980 by Djokic and co-workers, azithromycin has enjoyed considerable therapeutic success. |
| Biological Activity | Macrolide antibiotic. Inhibits 50S ribosomal subunit formation and elongation at transpeptidation step in gram-positive and gram-negative organisms. Orally active with improved pharmacokinetics over erythromycin in mouse models. |
| Azithromycin Preparation Products And Raw materials |
| Raw materials | Erythromycin |